fda glp-1 warning news november 2025 Last month, the issued 25 letters to telehealth companies over what it called false or misleading claims about compounded medications. Read more at the link in the comments below Trends In FDA FY 2025

Currently, theres no official retatrutide dosing information because the medication hasnt been approved yet by the United States Food and Drug Administration (FDA) and is not yet commercially available

Phase 2 trial dosing groups explained The trial randomized participants into seven groups

There are also common side effects in all classes of GLP-1s

If your FSA or HSA card is declined, you may complete your purchase using another payment method and contact [email protected] to request available documentation that may assist with reimbursement, subject to your plans requirements

Long-term studies show that GLP-1 medications remain safe and effective